Press Releases InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 February 10, 2022 Read More » InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector January 19, 2022 Read More » InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook January 5, 2022 Read More » Registration Now Open For Tribe Public’s Webinar Event “Addressing The Increasing Demand For Rare Cannabinoids” Featuring InMed’s Management Team On January 6, 2022 December 30, 2021 Read More » InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma December 20, 2021 Read More » InMed Announces Results of 2021 Annual General Meeting December 17, 2021 Read More » InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference November 23, 2021 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update November 10, 2021 Read More » InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid November 3, 2021 Read More » InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids October 13, 2021 Read More » InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa September 30, 2021 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update September 24, 2021 Read More » InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar “Accelerating The Commercialization of Rare Cannabinoids” September 17, 2021 Read More » InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021 September 17, 2021 Read More » InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids September 13, 2021 Read More » InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 9, 2021 Read More » InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th September 7, 2021 Read More » InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference August 12, 2021 Read More » InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules July 2, 2021 Read More » InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids June 29, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 February 10, 2022 Read More »
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector January 19, 2022 Read More »
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook January 5, 2022 Read More »
Registration Now Open For Tribe Public’s Webinar Event “Addressing The Increasing Demand For Rare Cannabinoids” Featuring InMed’s Management Team On January 6, 2022 December 30, 2021 Read More »
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma December 20, 2021 Read More »
InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference November 23, 2021 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update November 10, 2021 Read More »
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid November 3, 2021 Read More »
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids October 13, 2021 Read More »
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa September 30, 2021 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update September 24, 2021 Read More »
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar “Accelerating The Commercialization of Rare Cannabinoids” September 17, 2021 Read More »
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021 September 17, 2021 Read More »
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids September 13, 2021 Read More »
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 9, 2021 Read More »
InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th September 7, 2021 Read More »
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference August 12, 2021 Read More »
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules July 2, 2021 Read More »
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids June 29, 2021 Read More »
